Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III trial of setmelanotide in patients with pro-opiomelanocortin (POMC) deficiency obesity

Next Previous
Trial Profile

A phase III trial of setmelanotide in patients with pro-opiomelanocortin (POMC) deficiency obesity

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Setmelanotide (Primary)
  • Indications Obesity
  • Focus Registrational; Therapeutic Use
  • Sponsors Rhythm

    • Most Recent Events

    • 14 Oct 2021 According to a Rhythm media release, results of post-hoc analyses presented at the Obesity Medicine Association's Overcoming Obesity 2021 Conference and its Digital Experience (DX).
    • 14 Oct 2021 Results of post-hoc analyses published in the Rhythm Media Release.
    • 23 Jul 2021 According to a Rhythm Pharmaceuticals media release, the European Commission (EC) has granted marketing authorization to IMCIVREE (setmelanotide) in the European Union (EU) for the treatment of obesity and the control of hunger associated with genetically confirmed loss-of-function biallelic pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or biallelic leptin receptor (LEPR) deficiency in adults and children 6 years of age and above.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top